

The Epidemiology, Phenotype and Disease Course of Australian Children with Inflammatory Bowel Disease.

Dr Rammy Abu-Assi

Discipline/School: Paediatrics

University of Adelaide

April, 2014

Table of Contents

Chapter	Title	Page
	Index of Tables	13
	Index of Figures	17
	Abbreviations	19
	Abstract	21
	Declaration Statement	23
	Acknowledgement	24
1	Introduction	25
2	Epidemiology of Paediatric Onset Inflammatory Bowel Disease	27
2.1	Introduction	27
2.2	Limitations in comparing Epidemiological Studies	28
2.2.1	Defined upper age limit of the Paediatric Cohort	28
2.2.2	Diagnostic Criteria for IBD and Disease Subtype	28
2.2.3	Population Size	31
2.2.4	Retrospective versus Prospective Studies	31
2.2.5	Case Ascertainment	32
2.2.6	Derivation of Incidence Figures	33
2.3	Incidence of IBD	33
2.3.1	Geographical Differences in Incidence	35
2.3.2	Is the Incidence of Paediatric IBD Changing?	36
2.3.3	Differences between Urban and Rural areas	38
2.3.4	What Influence does Age have on the Incidence of IBD	38
2.3.5	Duration of Symptoms prior to Diagnosis	41
2.3.6	Does the Gender Distribution of IBD vary with Age	42
2.3.7	Impact of Ethnicity	42
2.3.8	Importance of Environmental Factors on the incidence of Paediatric onset IBD	44
2.4	Conclusion	45
3	Phenotype at Diagnosis of paediatric onset Inflammatory Bowel Disease	46
3.1	Introduction	46
3.2	Presenting Symptoms and Signs	46
3.3	Disease Distribution within the Gastrointestinal Tract	48
3.3.1	Disease Extent in Crohn's Disease	51
3.3.2	Disease Extent in Ulcerative Colitis	54
3.3.3	Disease Extent in Inflammatory Bowel Disease unclassified	55
3.3.4	Perianal Disease in IBD	55
3.3.5	Orofacial manifestations of IBD	56
3.4	CD Behaviour	57
3.5	Extra-intestinal manifestations of IBD	58

3.5.1	Musculoskeletal EIMs	60
3.5.2	Hepatobiliary EIMs	60
3.5.3	Cutaneous EIMs	61
3.5.4	Ocular EIMs	62
3.5.5	Other EIMs	62
3.6	Metabolic bone disease	63
3.7	Growth Issues in IBD	64
3.8	Pubertal Changes	67
3.9	Laboratory Parameters	67
3.10	Serology	68
3.11	Granulomata in CD	70
3.12	Familial Association of IBD	71
3.13	Genetic Impact on IBD Phenotype	73
3.14	Conclusion	74
4	Discussion of Disease Course in Paediatric onset Inflammatory Bowel Disease	75
4.1	Introduction	75
4.2	Disease Course according to Clinical Symptoms and Signs	75
4.2.1	Clinical Activity of CD over Time	78
4.2.2	Clinical Activity of UC over Time	79
4.3	Changes in Anatomical Disease Extent over Time	80
4.3.1	Crohn's Disease	80
4.3.2	Ulcerative Colitis	81
4.4	Changes in the Behaviour of Crohn's Disease	82
4.5	Change in Diagnosis	83
4.6	Efficacy of Response to Systemic Corticosteroids as a Predictor of Disease Course	84
4.6.1	Describing Disease Course of CD according to Systemic Corticosteroid Efficacy	85
4.6.2	Describing Disease Course of UC according to Systemic Corticosteroid Efficacy	86
4.7	Disease Course according to the Introduction of Immunomodulators/Biological Agents	86
4.8	Describing Disease Course according to Hospitalisation	86
4.8.1	Duration of Hospitalisation	87
4.9	Need for Surgery	88
4.9.1	Surgery in Crohn's Disease	88
4.9.2	Colectomy in Ulcerative Colitis	90
4.10	Nutrition and Growth	91
4.10.1	Crohn's Disease	92
4.10.1.1	Changes in Weight following Diagnosis	92
4.10.1.2	Changes in Height over the Disease Course	92
4.10.1.3	Influences on Nutrition and Growth in Crohn's Disease	93

4.10.1.3.1	Influence of Gender	93
4.10.1.3.2	Diagnostic Age	94
4.10.1.3.3	Impact of the Diagnostic Weight and Height Parameters on Subsequent Growth	94
4.10.1.3.4	Other Factors	94
4.10.1.3.5	Impact of Therapy	95
4.10.2	Ulcerative Colitis	95
4.11	Future Risk of Cancer	95
4.11.1	Ulcerative Colitis	95
4.11.2	Crohn's Disease	96
4.12	Mortality	96
4.12.1	Crohn's Disease	97
4.12.2	Ulcerative Colitis	97
4.13	Conclusion	98
5	Description of Disease Phenotype in Australian Children Diagnosed with Inflammatory Bowel Disease	99
5.1	Introduction	99
5.2	Aims and Hypothesis	99
5.3	Methodology	99
5.3.1	Australian Paediatric and Adolescent Inflammatory Bowel Disease Database (APAIBD)	99
5.3.2	Missing Incident Cases of IBD in South Australia	102
5.3.3	Statistical Analysis	102
5.3.4	South Australian Incidence Figures	103
5.3.5	Ethics Approval	104
5.4	Analysis of the National Database	105
5.4.1	APAIBD Database	105
5.4.2	Age Related Differences in Disease Subtype	106
5.4.3	Gender	108
5.4.4	Crohn's Disease	108
5.4.4.1	Anatomical Extent of Disease	108
5.4.4.2	Influence of Age and Gender on Disease Extent	109
5.4.4.3	CD Behaviour at Diagnosis	110
5.4.4.4	Presence of Granulomata	111
5.4.4.5	Serological Markers in CD	111
5.4.4.5.1	ASCA IgA/IgG Positivity	111
5.4.4.5.2	p-ANCA Positivity	112
5.4.5	Ulcerative Colitis	113
5.4.5.1	Age and Gender related differences in Disease Distribution	113
5.4.5.2	Other Gastrointestinal Disease Involvement in UC	115
5.4.5.3	p-ANCA Positivity and its Associated Significance	115
5.4.6	Inflammatory Bowel Disease Unclassified	115
5.4.7	Positive First Degree Family History of IBD	116

5.4.8	Laboratory Parameters	116
5.4.9	Discussion	117
5.4.9.1	Predominance of Crohn's Disease	117
5.4.9.2	Age-related Changes in Disease Subtype	117
5.4.9.3	Gender related Differences in Disease Subtype	118
5.4.9.4	Crohn's Disease	119
5.4.9.4.1	Anatomical Distribution of Crohn's Disease	119
5.4.9.4.2	Influence of Age on Disease Distribution	120
5.4.9.4.3	Behaviour of Crohn's Disease at Diagnosis	121
5.4.9.4.4	Importance of Granulomata in Crohn's Disease	121
5.4.9.4.5	Importance of ASCA Serology in Crohn's Disease	122
5.4.9.4.6	Significance of p-ANCA Positivity in Crohn's disease	122
5.4.9.5	Ulcerative colitis	123
5.4.9.5.1	Colonic Extent of Disease in Australian Children	123
5.4.9.5.2	Age-related Differences in Disease Extent	123
5.4.9.5.3	Importance of p-ANCA Positivity in Ulcerative Colitis	124
5.4.9.6	Inflammatory Bowel Disease Unclassified	124
5.4.10	Conclusion	124
5.5	Orofacial Crohn's Disease	125
5.5.1	Analysis of Orofacial Crohn's Disease	125
5.5.1.1	Age related Differences	126
5.5.1.2	Anatomical Extent of Disease	126
5.5.1.3	Association with Disease Behaviour	127
5.5.1.4	Association with Perianal Disease	127
5.5.1.5	Association between Orofacial CD and Extra-intestinal manifestations	128
5.5.1.6	Presence of Granulomata in Orofacial CD	129
5.5.1.7	Laboratory Abnormalities in Children with Orofacial CD	129
5.5.1.8	Anthropometric Data in Children with Orofacial Crohn's Disease	130
5.5.2	Discussion of Orofacial Crohn's Disease	130
5.5.2.1	Frequency of Orofacial Lesions	130
5.5.2.2	Age and Gender related Differences	131
5.5.2.3	Association with Disease Distribution	131
5.5.2.4	Association with Ocular and Dermatological Extra-Intestinal Manifestations	132
5.5.2.5	Importance of Orofacial Biopsies and Relevance of Granulomata	132
5.5.3	Conclusion	132
5.6	Perianal Crohn's Disease	133
5.6.1	Analysis of Perianal Crohn's Disease	133
5.6.1.1	Strong Relationship between Perianal Lesions	134
5.6.1.2	Age related Differences in Frequency	135
5.6.1.3	Gender related Differences in Perianal Lesions	136
5.6.1.4	Association between Perianal Disease and Anatomical Involvement of Crohn's Disease at Diagnosis	136

5.6.1.5	Relationship between Orofacial Crohn's Disease and Perianal Lesions	137
5.6.1.6	Impact of Intestinal Disease Behaviour on Perianal Lesions	137
5.6.1.7	Association with Extra-Intestinal Manifestations	137
5.6.1.8	Laboratory Abnormalities in Children with Perianal Lesions at Diagnosis	138
5.6.1.9	Impact of Perianal Disease upon Anthropometric Parameters	139
5.6.2	Discussion of Perianal Disease in Crohn's disease	139
5.6.2.1	High frequency of Perianal Lesions	139
5.6.2.2	Association between Perianal Lesions	140
5.6.2.3	Aged related difference in Frequency of Anal Tags	140
5.6.2.4	Gender differences in Type of Perianal Lesions	140
5.6.2.5	Association with Anatomical Extent of Disease	140
5.6.2.6	Relationship with Intestinal Behaviour	141
5.6.2.7	Association with Extra-Intestinal Manifestations	141
5.6.2.8	Reduced Frequency of Perianal Disease in p-ANCA positive Children	141
5.6.3	Conclusion	142
5.7	Extra-Intestinal Manifestations in IBD	143
5.7.1	Analysis of Extra-Intestinal Manifestations	143
5.7.1.1	Hepatobiliary Manifestations	143
5.7.1.1.1	Association between Hepatobiliary EIMs and Phenotype at Diagnosis	144
5.7.1.1.2	Sclerosing Cholangitis	144
5.7.1.2	Musculoskeletal Manifestations in IBD	145
5.7.1.2.1	Association between Musculoskeletal Manifestations and Phenotype at Diagnosis	145
5.7.1.3	Ocular Extra-Intestinal Manifestation	146
5.7.1.3.1	Association between Ocular EIMs and Disease Phenotype	146
5.7.1.4	Dermatological Extra-Intestinal Manifestations	147
5.7.1.4.1	Association with Disease Phenotype	148
5.7.1.4.2	Erythema Nodosum in Crohn's Disease	148
5.7.1.5	Aphthous Ulcers of the Mouth	149
5.7.1.5.1	Associations with Disease Phenotype at Diagnosis	149
5.7.2	Discussion of Extra-Intestinal Manifestations	149
5.7.2.1	Frequency of Extra-Intestinal Manifestations	150
5.7.2.2	Hepatobiliary Extra-Intestinal Manifestations	150
5.7.2.3	Musculoskeletal Extra-Intestinal Manifestations	151
5.7.2.4	Ophthalmological Extra-Intestinal Manifestations	151
5.7.2.5	Dermatological Manifestations	152
5.7.2.6	Mouth Ulcers	152
5.7.3	Conclusion	153
5.8	Anthropometric Parameters at Diagnosis	154
5.8.1	Diagnostic Weight	154

5.8.1.1	Crohn's disease	154
5.8.1.2	Ulcerative Colitis	155
5.8.1.3	Inflammatory Bowel Disease Unclassified	155
5.8.2	Diagnostic Height	157
5.8.2.1	Crohn's Disease	157
5.8.2.2	Ulcerative Colitis	158
5.8.2.3	Inflammatory Bowel Disease Unclassified	158
5.8.3	Diagnostic Body Mass Index	158
5.8.3.1	Crohn's Disease	158
5.8.3.2	Ulcerative Colitis	159
5.8.3.3	Inflammatory Bowel Disease Unclassified	159
5.8.4	Discussion of Anthropometric Data at Diagnosis	159
5.8.4.1	Crohn's Disease	160
5.8.4.1.1	Impact of Age at Diagnosis	160
5.8.4.1.2	Prolonged Delay in Diagnosis associated with worsening Anthropometric Parameters	161
5.8.4.1.3	Impact of Pubertal Stage upon Anthropometric Data	161
5.8.4.1.4	Impact of Anatomical Site of Disease	161
5.8.4.1.5	Stricture Disease Behaviour (B2) contributed to Worsened Nutrition	162
5.8.4.1.6	Association between Perianal Disease and Poorer Anthropometric Parameters	162
5.8.4.1.7	ASCA IgA positivity predicted Worsened Anthropometric Parameters at Diagnosis	162
5.8.4.1.8	Lack of Gender Differences	162
5.8.4.2	Ulcerative Colitis	163
5.8.5	Limitations of Anthropometric Analysis	163
5.8.5.1	Assessing Anthropometric Parameters according to Bone Age	163
5.8.5.2	Height Velocity may be a Better Measure	163
5.8.6	Conclusion	164
5.9	Are there any Regional Variation in Disease Phenotype between the Australian states?	165
5.9.1	Comparison between the Australian States	165
5.9.1.1	Disease Subtype within and between the various States	165
5.9.1.2	Gender Differences	165
5.9.1.3	Gastrointestinal Disease Extent in CD among the States	166
5.9.1.4	Orofacial and Perianal disease in CD among the States	167
5.9.1.5	Disease Behaviour in Crohn's disease between the States	168
5.9.1.6	Disease Extent in UC	168
5.9.1.7	Comparison between the Western and Eastern parts of Australia	169
5.9.1.7.1	Overall IBD cohort	169
5.9.1.7.2	Crohn's Disease	170
5.9.1.7.3	Ulcerative Colitis	172
5.9.1.8	Comparison of Disease Phenotype between the Northern and	172

	Southern parts of Australia	
5.9.1.8.1	Overall IBD cohort	172
5.9.1.8.2	Crohn's Disease	173
5.9.1.8.3	Ulcerative Colitis	174
5.9.2	Discussion of Regional Differences	175
5.9.2.1	Differences between the States	175
5.9.2.2	Better Data Collection	176
5.9.3	Conclusion	176
5.10	Incidence of IBD in South Australia	177
5.10.1	Analysis of South Australian Data	177
5.10.2	Discussion of South Australian Incidence	179
5.10.2.1	Comparison of South Australian incidence figures to Other Regions	179
5.10.2.2	Temporal Changes in Incidence of IBD	181
5.10.2.3	Regional Variation within the State	181
5.10.2.4	Accuracy of Incidence Figures	182
5.10.3	Conclusion	182
5.11	Concluding Remarks on Disease Phenotype at Diagnosis	183
6	Follow-up of South Australian children diagnosed with Inflammatory Bowel Disease	184
6.1	Introduction	184
6.2	Aims and Hypothesis	184
6.3	Methodology	184
6.3.1	Recruitment of Children	184
6.3.2	Phenotypic Features at Diagnosis	185
6.3.3	Medical Therapy	185
6.3.4	Follow-up Data	185
6.3.5	Clinical Parameters of Disease Course	185
6.3.5.1	Corticosteroid Use	186
6.3.5.2	Clinical Disease Activity	186
6.3.5.3	Changes in Anatomical Disease Extent	187
6.3.5.4	Development of Complicating Crohn's Disease Behaviour	187
6.3.5.5	Hospitalisation	187
6.3.5.6	Major Surgery	187
6.3.5.7	Anthropometric Parameters	188
6.3.6	Statistical Analysis	188
6.3.7	Ethics Approval	189
6.4	Analysis of South Australian Cohort at Diagnosis	190
6.4.1	Description of Cohort at Diagnosis	190
6.4.2	Diagnostic evaluation	192
6.4.3	Crohn's Disease Cohort	192
6.4.4	Ulcerative Colitis Cohort	195
6.4.5	Discussion of South Australian Phenotype at Diagnosis	195
6.4.6	Conclusion	196

6.5	Induction Period (first 16 weeks following diagnosis/induction therapy)	197
6.5.1	Hospitalisation	198
6.5.2	Crohn's Disease	198
6.5.2.1	Clinical Remission Rates	198
6.5.2.2	Induction Therapy in Crohn's Disease	198
6.5.2.3	Predictors of Clinical Remission in Children treated with Systemic Corticosteroids	199
6.5.2.4	Corticosteroid Efficacy	199
6.5.2.5	Surgery during Induction Period	199
6.5.3	Ulcerative Colitis	200
6.5.3.1	Overall Clinical Remission Rates within the Induction Period	200
6.5.3.2	Induction Therapy in Ulcerative Colitis	200
6.5.3.3	Systemic Corticosteroids as Induction Therapy	200
6.5.3.4	Calcineurin Inhibitor Use	201
6.5.3.5	Surgery during Induction Period	201
6.5.4	Early Use of Azathioprine during the Induction Period	202
6.5.5	Discussion of Induction Period	203
6.5.5.1	Clinical Remission Rates	203
6.5.5.2	Predictors for Lack of Response to Systemic Corticosteroids	203
6.5.5.3	Comparison between Corticosteroids and Enteral Nutrition as Induction Therapy for Crohn's Disease	204
6.5.5.4	Appropriateness of Clinical Remission as a Therapeutic Goal	204
6.5.5.5	Need for Calcineurin Inhibitors (Cyclosporine) in Ulcerative Colitis	205
6.5.5.6	Early Azathioprine Use in Crohn's Disease and Ulcerative Colitis	205
6.5.6	Conclusion	205
6.6	Follow-up Period	206
6.6.1	Change in Diagnosis	206
6.6.2	Medications during Follow-up Period	207
6.7	Change in Anatomical Extent of Disease	208
6.7.1	Crohn's Disease	210
6.7.1.1	Disease Extension in Crohn's Disease	210
6.7.1.2	Disease Regression in Crohn's Disease	211
6.7.1.3	Mucosal Healing in Crohn's Disease	211
6.7.1.4	Development of Orofacial Crohn's Disease	212
6.7.1.5	Development of Perianal Crohn's Disease	212
6.7.2	Ulcerative Colitis	212
6.7.2.1	Disease Extension in Ulcerative Colitis	212
6.7.2.2	Disease Regression in Ulcerative Colitis	212
6.7.2.3	Mucosal Healing in Ulcerative Colitis	213
6.7.3	Progression to Intestinal Strictureing/Fistulising Complications in Crohn's Disease	213
6.7.4	Discussion of Anatomical Disease Extent Change and Complicating Behaviour Development	215

6.7.4.1	Anatomical Disease Extension	215
6.7.4.2	Anatomical Disease Regression	216
6.7.4.3	Mucosal Healing	217
6.7.4.4	Development of Complicating Behaviour in Crohn's Disease	218
6.7.5	Limitations of this Study	218
6.7.5.1	Nature of this Study	218
6.7.5.2	Under-estimation of Cumulative Rates	219
6.7.5.3	Differences in Statistics	219
6.7.6	Conclusion	219
6.8	Description of Clinical Disease Activity	220
6.8.1	Subsequent Clinical Relapse following the Induction Period	220
6.8.1.1	Crohn's Disease	220
6.8.1.2	Ulcerative Colitis	222
6.8.2	Occurrence of Persistent Clinical Disease	223
6.8.3	Impact of Early Introduction of Azathioprine	226
6.8.4	Discussion of Results	226
6.8.4.1	Risk of Subsequent Clinical Relapse	226
6.8.4.1.1	Crohn's Disease	226
6.8.4.1.2	Ulcerative Colitis	227
6.8.4.2	Persistent Clinical Disease	228
6.8.5	Limitations	228
6.8.5.1	Definition of Relapses and Persistent clinical Disease	228
6.8.5.2	Sample Size	229
6.8.5.3	Bias	229
6.8.6	Conclusion	229
6.9	Systemic Corticosteroid Use	230
6.9.1	Corticosteroid Efficacy within the First Year	230
6.9.1.1	Crohn's Disease	230
6.9.1.2	Ulcerative Colitis	230
6.9.2	Predictors of Corticosteroid Refractory or Dependent Crohn's disease within the First Year	230
6.9.2.1	Crohn's Disease	230
6.9.2.2	Ulcerative Colitis	231
6.9.3	Duration of Corticosteroid Therapy	232
6.9.3.1	Crohn's Disease	232
6.9.3.2	Ulcerative Colitis	233
6.9.4	Discussion of Systemic Corticosteroid Efficacy and Duration	234
6.9.4.1	Corticosteroid Efficacy within the First Year	234
6.9.4.1.1	Crohn's Disease	234
6.9.4.1.2	Ulcerative Colitis	235
6.9.4.2	Predictors of Corticosteroid Refractoriness and Dependency within the First Year	236
6.9.4.2.1	Crohn's Disease	236
6.9.4.3	Corticosteroid Duration	237

6.9.4.3.1	Crohn's Disease	237
6.9.4.3.2	Ulcerative Colitis	237
6.9.4.4	Limitation of the Study	237
6.9.4.4.1	Description of Clinical Symptoms	237
6.9.4.4.2	Definition of Corticosteroid Efficacy	238
6.9.4.4.3	Differences in Corticosteroid Response End Points	238
6.9.4.4.4	Corticosteroid Dosing	239
6.9.4.4.5	Paucity of Studies	239
6.9.5	Conclusion	239
6.10	Hospitalisation	240
6.10.1	Duration of Hospitalisation Analysis	240
6.10.1.1	Predictors for Duration of Hospitalisation	240
6.10.1.1.1	Crohn's Disease	240
6.10.1.1.2	Ulcerative Colitis	242
6.10.2	Discussion of Hospitalisation	244
6.10.2.1	Duration of Hospitalisation within the First Five Years	244
6.10.2.2	Predictors of Longer Hospitalisation	244
6.10.2.2.1	Crohn's Disease	244
6.10.2.2.2	Ulcerative Colitis	245
6.10.3	Limitation of the Study	246
6.10.4	Conclusion	246
6.11	Major Surgery	247
6.11.1	Overview of Major Surgery	247
6.11.2	Surgical Rates within the First Five Years	250
6.11.3	Predictors of Major Surgery within the First Five Years	251
6.11.4	Predictors of Shorter Duration to Major Surgery	252
6.11.5	Impact of Early Azathioprine Use	253
6.11.6	Discussion of Major Surgery	253
6.11.6.1	Surgical Rates	253
6.11.6.1.1	Crohn's Disease	253
6.11.6.1.2	Ulcerative Colitis	254
6.11.6.2	Predictors of Surgery	255
6.11.6.2.1	Crohn's Disease	255
6.11.6.2.2	Ulcerative Colitis	255
6.11.6.3	Shorter Interval to Surgery	256
6.11.6.3.1	Crohn's Disease	256
6.11.6.3.2	Ulcerative Colitis	256
6.11.6.4	Impact of Early Azathioprine Use	257
6.11.7	Limitation	257
6.11.7.1	Small Cohort	257
6.11.7.2	Retrospective Review of Case-notes/Electronic Database	257
6.11.8	Conclusion	258
6.12	Growth	259
6.12.1	Analysis of Growth	259

6.12.2	Weight z-scores at Diagnosis and Follow-up	262
6.12.2.1	Crohn's Disease	262
6.12.2.2	Ulcerative Colitis	262
6.12.3	Height z-scores at Diagnosis and Follow-up	264
6.12.4	BMI z-scores at Diagnosis and Follow-up	265
6.12.4.1	Crohn's Disease	265
6.12.4.2	Ulcerative Colitis	265
6.12.5	Predictors of Anthropometric Parameters at Diagnosis	267
6.12.6	Predictors of Anthropometric Parameters in Pre/Early Pubertal Children at one, two and five years following Diagnosis	270
6.12.6.1	Weight z-scores following Diagnosis	270
6.12.6.1.1	Crohn's Disease	270
6.12.6.1.2	Ulcerative Colitis	272
6.12.6.2	Height z-scores following Diagnosis	273
6.12.6.2.1	Crohn's Disease	273
6.12.6.2.2	Ulcerative Colitis	275
6.12.6.3	BMI z-scores following Diagnosis	276
6.12.6.3.1	Crohn's Disease	276
6.12.6.3.2	Ulcerative Colitis	278
6.12.6.4	Predictors of Anthropometric Changes following Diagnosis in Pre/Early Pubertal Children	279
6.12.6.4.1	Weight z-scores	279
6.12.6.4.1.1	Crohn's Disease	279
6.12.6.4.1.2	Ulcerative Colitis	281
6.12.6.4.2	Height z-scores	282
6.12.6.4.2.1	Crohn's Disease	282
6.12.6.4.2.2	Ulcerative Colitis	283
6.12.6.4.3	BMI z-scores	283
6.12.6.4.3.1	Crohn's Disease	283
6.12.6.4.3.2	Ulcerative Colitis	284
6.12.6.5	Impact of Systemic Corticosteroid Duration and Early Azathioprine Use	285
6.12.7	Discussion of Anthropometric Data	285
6.12.7.1	Significant Impairment in Diagnostic Anthropometric Parameters in Children with Crohn's disease	285
6.12.7.2	Trend in Anthropometrics following Diagnosis	285
6.12.7.2.1	Crohn's Disease	285
6.12.7.2.1.1	Weight and BMI	285
6.12.7.2.1.2	Height	286
6.12.7.2.2	Ulcerative Colitis	287
6.12.7.3	Predictors of Anthropometric Parameters at Diagnosis	287
6.12.7.3.1	Crohn's Disease	287
6.12.7.3.1.1	Weight and BMI z-scores at Diagnosis	287
6.12.7.3.1.2	Height z-scores at diagnosis	288

6.12.7.3.2	Ulcerative Colitis	288
6.12.7.4	Predictors of Weight and BMI changes following Diagnosis	289
6.12.7.4.1	Impact of Diagnostic Anthropometric Parameters	289
6.12.7.4.2	Crohn's Disease	289
6.12.7.4.2.1	Weight/BMI z-scores	289
6.12.7.4.2.2	Height z-scores	290
6.12.7.4.3	Ulcerative Colitis	291
6.12.8	Limitation	291
6.12.9	Conclusion	292
6.13	Mortality	293
6.14	Conclusion on Disease Course in Children with Inflammatory Bowel Disease	294
7	Contribution to Current Literature (Overall Conclusion)	295
	Appendix A	297
	Appendix B	299
	Appendix C	303
	Bibliography	305

Index of Tables

Table	Title	Page
2.1	Lennard-Jones criteria for the diagnosis of CD and UC.	29
2.2	Endoscopic and histological differentiation between CD and UC according to Porto criteria.	30
2.3	International studies of the incidence of IBD in children (≤ 18 years).	34
2.4	Incidence figures of CD and UC in children among the various provinces in Canada (1998-2000).	35
3.1	Presenting symptoms/signs of IBD.	47
3.2	The Montreal classification of CD.	49
3.3	The Montreal classification of UC.	49
3.4	Paris modification of the Montreal Classification of CD.	50
3.5	Paris modification of the Montreal Classification for UC.	50
3.6	Distribution of disease in children diagnosed with CD.	52
3.7	Disease distribution among various UC studies.	54
3.8	Reported diagnostic weight, height and BMI parameters in children with IBD.	66
4.1	Paediatric Ulcerative Colitis Activity Index (PUCAI).	77
4.2	Paediatric CD activity index (PCDAI).	297
4.3	Intra-abdominal surgical rates in children with CD following diagnosis.	89
4.4	Frequency of colonic resection in children with UC.	91
5.4.1	Details of the children with IBD at time of diagnosis.	106
5.4.2	Comparison of phenotypic presentation of children with CD, UC, IBDU.	107
5.4.3	Characteristics of the children according to lower gastrointestinal disease distribution.	109
5.4.4	Disease behaviour at diagnosis according to age.	111
5.4.5	Comparison of disease phenotype of children with CD who were ASCA IgA and/or IgG positive.	112
5.4.6	Characteristics of children with UC.	114
5.4.7	Phenotypic characteristics of children diagnosed with IBDU.	116
5.4.8	Laboratory parameters at diagnosis.	117
5.5.1	Phenotypic features at diagnosis of children with orofacial CD (OFD) compared to the rest of the cohort.	125
5.5.2	Frequency of OFD according to the 6 years age group.	126
5.5.3	Frequency of disease within the upper gastrointestinal tract in children with orofacial CD.	127
5.5.4	Frequency of perianal disease in children with OFD.	127
5.5.5	Frequency of perianal disease with OFD among male and female children.	128
5.5.6	Frequency of extra-intestinal manifestations in children with orofacial disease.	129
5.5.7	Comparison of laboratory parameters in OFD compared to non-OFD.	130
5.6.1	Frequency of perianal disease in CD.	133
5.6.2	Phenotypic details of children presenting with perianal disease compared to the rest of the cohort.	134

5.6.3	Association between various perianal lesions in a multi-logistic regression analysis.	135
5.6.4	Age related frequency of perianal lesions.	135
5.6.5	Gender related differences in the frequency of perianal lesions.	136
5.6.6	Frequency of specific EIMs in those children with or without perianal disease.	138
5.6.7	Comparison of laboratory parameters in children with or without perianal lesions.	139
5.7.1	Extra-intestinal manifestations in children diagnosed with IBD.	143
5.7.2	Number of children with each type of hepatobiliary disorder.	145
5.7.3	Number of children with musculoskeletal EIMs.	146
5.7.4	Number of children with eye disorders in IBD.	147
5.7.5	Number of children with dermatological lesions.	149
5.8.1	Median anthropometric parameters at diagnosis in children with CD according to phenotypic features.	156
5.8.2	Anthropometrics of children diagnosed with UC.	157
5.8.3	Comparison of the z-scores for weight, height and BMI and frequency of failure between Australian children and other international cohorts diagnosed with CD or UC.	160
5.9.1	IBD phenotype at diagnosis among the Australian states.	165
5.9.2	Distribution of CD behaviour between the various states.	168
5.9.3	Extent of colitis in children diagnosed with UC between states.	169
5.9.4	Comparison between Western and Eastern parts of Australia with regard to IBD diagnosis.	170
5.9.5	Differences in CD phenotype at diagnosis between the Western and Eastern parts of Australia.	171
5.9.6	Comparison of phenotypic features at diagnosis in children with UC between the West and Eastern parts of Australia.	172
5.9.7	Characteristics of children diagnosed with IBD between Northern and Southern parts of Australia.	173
5.9.8	Phenotypic features at diagnosis of children with CD between the Northern and Southern parts of Australia.	174
5.9.9	Phenotypic features of children diagnosed with UC between the Northern and Southern regions of Australia.	175
5.10.1	Children diagnosed with IBD in South Australia (1996-2009).	178
5.10.2	Incidence of IBD among the different regions of South Australia (1996-2009).	179
5.10.3	Incidence figures of children diagnosed with IBD for Australasia compared to other cohorts.	180
6.4.1	Phenotypic details at diagnosis of South Australian children with IBD.	191
6.4.2	Frequency of specific extra-intestinal manifestations (EIMs) at diagnosis in South Australian children.	191
6.4.3	Laboratory parameters at diagnosis among the disease subtypes.	192
6.4.4	Anatomical distribution and disease behaviour of CD in South Australian	194

	children.	
6.5.1	List of medications used for induction therapy.	197
6.5.2	Differences in laboratory values at diagnosis in children with UC who were corticosteroid responsive and refractory.	201
6.5.3	Factors at time of diagnosis predictive of cyclosporine use in children treated with corticosteroids.	201
6.5.4	Analysis of children with CD in whom azathioprine was initiated within the induction period.	202
6.5.5	Analysis of children with UC in whom azathioprine was initiated within the induction period.	203
6.6.1	List of medications used in CD and UC (with the exclusion of systemic corticosteroids).	207
6.8.1	Proportion of children with CD who achieved clinical remission during the induction period but subsequently developed a clinical relapse.	220
6.8.2	Predictive factors for at least one clinical relapse following initial remission during the induction period in children with CD.	221
6.8.3	Proportion of children with UC who achieved clinical remission at the end of the induction period but subsequently experienced a clinical relapse.	222
6.8.4	Factors predictive of a clinical relapse following remission during the induction period in children diagnosed with UC.	223
6.8.5	Number of children experiencing persistent disease following diagnosis.	225
6.9.1	Predictors of corticosteroid refractory and dependent CD at one year.	231
6.9.2	Features predictive of a longer duration of systemic corticosteroids use in children diagnosed with CD within the first five years.	233
6.9.3	Features predictive of a longer duration of systemic corticosteroids use in children diagnosed with UC within the first five years.	234
6.9.4	Comparison of corticosteroid efficacy at 1 year between South Australian children and other cohorts.	236
6.10.1	Predictors of duration of hospitalisation in children with CD within the first five years.	241
6.10.2	Predictors of duration of hospitalisation in children with UC within the first five years.	243
6.11.1	Details of initial major surgery in children with Crohn's disease.	248
6.11.2	Details of initial major surgery in children with ulcerative colitis.	249
6.11.3	Predictors of major surgery within the first 5 years in children with CD or UC.	251
6.11.4	Diagnostic features predictive of shorter duration to major surgery within the first five years.	252
6.11.5	Comparison of surgical rates in children diagnosed with CD.	254
6.11.6	Comparison of colectomy rates in children with UC.	255
6.12.1	Number of children with recorded anthropometric values at the various follow-up time points.	259
6.12.2	Number of children in Tanner stage 1 or 2 (pre/early puberty) at diagnosis and reviewed at the specified time periods.	260

6.12.3	Mean values for weight, height and BMI z-scores in children with CD.	261
6.12.4	Mean values for weight, height and BMI z-scores in children with UC.	261
6.12.5	Predictors for weight z-score values at diagnosis in children with CD.	267
6.12.6	Predictors for weight z-score values at diagnosis in children with UC.	267
6.12.7	Predictors for height z-score values at diagnosis in children with CD.	268
6.12.8	Predictors for height z-score values at diagnosis in children with UC.	268
6.12.9	Predictors for BMI z-score values at diagnosis in children with CD.	269
6.12.10	Predictors for BMI z-score values at diagnosis in children with UC.	269
6.12.11	Predictors for weight z-score values at 1, 2 and 5 years following diagnosis in pre/early pubertal children with CD.	271
6.12.12	Predictors for weight z-score values at 1, 2 and 5 years following diagnosis in pre/early pubertal children with UC.	272
6.12.13	Predictors for height z-score values at 1, 2 and 5 years following diagnosis in pre/early pubertal children with CD.	274
6.12.14	Predictors for height z-score values at 1, 2 and 5 years following diagnosis in pre/early pubertal children with UC.	275
6.12.15	Predictors for subsequent BMI z-score values in pre/early pubertal children diagnosed with CD.	277
6.12.16	Predictors for subsequent BMI z-score values in pre/early pubertal children diagnosed with UC.	278
6.12.17	Predictors for weight z-score change following diagnosis in pre/early pubertal children with CD.	280
6.12.18	Predictors for weight z-scores changes following diagnosis in pre/early pubertal children diagnosed with UC.	281
6.12.19	Predictors of change in height z-scores in pre/early pubertal children diagnosed with CD.	282
6.12.20	Predictors of change in height z-scores in pre/early pubertal children diagnosed with UC.	283
6.12.21	Predictors of change in BMI z-scores in pre/early pubertal children diagnosed with CD.	303
6.12.22	Predictors of change in BMI z-scores in pre/early pubertal children diagnosed with UC.	284
6.12.23	Anthropometric parameters at time of diagnosis in children with IBD compared to international studies.	285

Index of Figures

Figures	Title	Page
2.1	Changes in the incidence of paediatric CD over time.	36
2.2	Changes in the incidence of paediatric UC over time.	37
2.3	Incidence of IBD according to age at diagnosis in Manitoba, Canada.	39
2.4	Incidence of IBD according to age at diagnosis in Olmsted County, USA.	39
2.5	Incidence of IBD in children from Northern France during the period 1988-1999.	40
2.6	Number of children diagnosed with CD, UC and IBDU subtype according to age during the period of January 2000-November 2002	41
3.1	Disease distribution in Scottish children with CD.	53
3.2	Comparison of disease distribution in CD between children and adults from Scotland.	53
4.1	Disease extent in 281 children diagnosed with CD.	81
4.2	Changes in disease extent in 113 children with UC followed for at least 2 yrs.	82
4.3	Changes in disease behaviour of 404 children with CD followed for at least 2 years.	83
5.4.1	Year of age at diagnosis among the various disease subtypes.	107
5.4.2	Disease subtypes among the age groups.	108
5.4.3	Disease distribution within each 6 year age range.	110
5.4.4	Disease extent in UC at diagnosis according to age.	114
5.4.5	Disease distribution according to the Montreal classification among various paediatric cohorts.	120
5.4.6	Comparison of disease behaviour at diagnosis between APAIBD and other paediatric cohorts.	121
5.4.7	Comparison of colonic disease extent in APAIBD children with other paediatric cohorts.	123
5.7.1	Frequency of ocular disease in the presence of other extra-intestinal manifestations in children with IBD.	147
5.9.1	Interstate comparison of gastrointestinal tract disease distribution in CD.	166
5.9.2	Distribution of lower gastrointestinal tract disease in children with CD among the various states.	167
5.9.3	Distribution of orofacial and perianal lesions in children with CD among the states.	168
5.9.4	Extent of colitis in children diagnosed with UC between the various states.	169
5.10.1	Children diagnosed with IBD in South Australia between 1996 and 2009.	177
5.10.2	Incidence of IBD in South Australian children (1996-2009).	179
6.4.1	Extent of lower intestinal CD (L1-3) in children with upper gastrointestinal disease (L4).	194
6.5.1	Frequency of remission (PCDAI \leq 10) in children with CD.	198
6.5.2	Frequency of remission (PUCAI $<$ 10) in children with UC.	200
6.7.1	Kaplan-Meier survival curve for anatomical disease extension in CD and	208

	UC.	
6.7.2	Kaplan-Meier survival curve for disease regression in CD and UC.	209
6.7.3	Kaplan-Meier survival curve for mucosal healing in CD and UC.	210
6.7.4	Extension of lower gastrointestinal involvement in children with CD within the first 5 years.	211
6.7.5	Regression in lower gastrointestinal involvement in children with CD within the first 5 years.	211
6.7.6	Regression in extent of ulcerative colitis within the first 5 years.	212
6.7.7	Changes in Crohn's disease behaviour within the first 5 years following diagnosis.	213
6.7.8	Kaplan-Meier survival curve for the development of intestinal stricturing/fistulising complications in CD.	214
6.7.9	Development of intestinal stricturing/fistulising complications (B2/B3) in children with CD according to corticosteroid response during the induction period.	215
6.8.1	Kaplan-Meier survival analysis of time to first persistent disease episode in children diagnosed with CD or UC.	224
6.8.2	Development of persistent clinical disease in children with UC limited to the rectum (E1) compared to left sided/extensive colitis (E2/3).	226
6.11.1	Kaplan-Meier survival curve for major surgery in children with CD and UC.	250
6.12.1	Temporal changes in weight z-scores in the overall cohort.	263
6.12.2	Temporal changes in weight z-scores of pre/early pubertal children.	263
6.12.3	Temporal changes in height z-scores in the overall cohort.	264
6.12.4	Temporal changes in height z-scores in pre/early pubertal children.	264
6.12.5	Temporal changes in BMI z-scores in the overall cohort.	266
6.12.6	Temporal changes in BMI z-scores in pre/early pubertal children.	266

Abbreviations

ACT	Australian Capital Territory
ANOVA	Analysis of variance
APAIBD	Australian Paediatric and Adolescent Inflammatory Bowel Disease database
ASCA	Anti- <i>Saccharomyces cerevisiae</i>
ASA	Aminosalicylates
BMI	Body mass index
CARD15	Caspase recruitment domain-containing protein 15
CD	Crohn's disease
CI	Confidence interval
CRP	C-reactive protein
EIM	Extra-intestinal manifestation
ESR	Erythrocyte sedimentation rate
GIT	Gastrointestinal tract
Hb	Haemoglobin
HR	Hazards ratio
Ht	Height
IBD	Inflammatory bowel disease
IBD1	Inflammatory bowel disease protein 1
IBDU	Inflammatory bowel disease unclassified
IC	Indeterminate colitis
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IQR	Interquartile range
N	Number of children
NOD2	Nucleotide-binding oligomerization domain-containing protein 2
NSW	New South Wales
NT	Northern Territory
OFD	Orofacial Crohn's disease
OR	Odds ratio
p-ANCA	Perinuclear anti-nuclear cytoplasmic antibody
PCDAI	Paediatric Crohn's disease activity index
Plts	Platelets
PSC	Primary Sclerosing Cholangitis

PUCAI	Paediatric ulcerative colitis activity index
QLD	Queensland
SA	South Australia
SMR	Standardised mortality ratio
TAS	Tasmania
UC	Ulcerative colitis
UK	United Kingdom
USA	United States of America
VIC	Victoria
WA	Western Australia
WCC	White cell count
Wks	Weeks
Wt	Weight
Yrs	Years

Abstract

Inflammatory bowel disease (IBD) is the term for a group of disorders of the gastrointestinal tract, encompassing Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease unclassified (IBDU). The aims of this study were to review the disease phenotype at diagnosis in children with IBD, investigate any significant associations, determine the incidence in South Australia and to assess the disease course.

Methodology: Phenotypic features at diagnosis of children collected into the Australian Paediatric and Adolescent IBD database (APAIBD) and follow-up details of South Australian children were analysed. Incidence of IBD in South Australia was calculated. Statistical testing included the independent t-tests/ANOVA (parametric), Mann-Whitney/Kruskal-Wallis testing (non-parametric), chi-square analysis, linear and logistic regression, Kaplan-Meier survival, Cox Proportional Hazards, negative binomial regression and linear mixed effects model. $P < 0.05$ was considered to be statistically significant.

Results: There were 2101 children diagnosed with IBD during the period 1996-June, 2010. The majority had CD (1247; 59.4%), followed by UC (631; 30%) and IBDU (223; 10.6%). Overall, there was a male predominance (56.4%), which was significantly greater in CD compared to the background Australian paediatric population (58.6% vs 51.3%; $p < 0.05$). The majority of children with CD presented with ileocolonic disease (57%; 662), upper gastrointestinal inflammation (78.9%; 816) and inflammatory behaviour (92.6%; 1123). Orofacial CD was present at diagnosis in 8.9% (107/1207) and perianal lesions in 46% (545/1184) of children. There was a significant association between orofacial CD and anal tags ($p < 0.0001$), anal fissures ($p < 0.0001$), oesophageal inflammation ($p = 0.0001$), ocular ($p = 0.0016$) and dermatological manifestations ($p = 0.001$). Most children with UC presented with extensive colitis (69.6%; 421/605). Children with CD presented with a lower weight, height and BMI z-scores compared to UC. The incidence of IBD, CD and UC in South Australian children aged less than 16 years was 6.43, 3.62 and 2.31 per 100,000 person years respectively during 1996-2009.

The majority of children were treated with systemic corticosteroids (85% CD; 70% UC) with a clinical remission rate of at least 70% at 6 weeks. Half of these children had a subsequent clinical flare-up within the first year. Compared to CD, a greater proportion of children with UC developed mucosal healing within 5 years ($p = 0.0037$). The risk of developing intestinal strictures or fistulae was 15% at 5 years in CD. Mean duration of systemic corticosteroid use

was 69.3 and 59.7 days per year for CD and UC, respectively. The mean duration of hospitalisation was 5.29 days per year for CD and 6.07 days per year for UC. The rates of intra-abdominal surgery were 16% in CD and 13% in UC within the first 5 years. Weight and BMI parameters improved within the first year following diagnosis in both CD and UC, although the low height z-scores in CD did not improve, despite medical therapy. Two children with CD died as a result of sepsis.

Conclusion: Paediatric IBD is a heterogeneous disease, which impacts upon a child's health. Despite attaining remission, children are at risk of clinical recurrence, changes in extent and behaviour, side-effects from systemic corticosteroids, surgery and poor growth. Thus, there is a need for improved management to avoid these complications.

Declaration Statement

I certify that this work contains no material which has been accepted for the award of any other degree or diploma in any university or other tertiary institution and, to the best of my knowledge and belief, contains no material previously published or written by another person, except where due reference has been made in the text. In addition, I certify that no part of this work will, in the future, be used in a submission for any other degree or diploma in any university or other tertiary institution without the prior approval of the University of Adelaide and where applicable, any partner institution responsible for the joint award of this degree.

I give consent to this copy of my thesis, when deposited in the University Library, being made available for loan and photocopying, subject to the provisions of the Copyright Act 1968.

I also give permission for the digital version of my thesis to be made available on the web, via the University's digital research repository, the Library catalogue and also through web search engines, unless permission has been granted by the University to restrict access for a period of time.

Dr Rammy Abu-Assi,
1st of April, 2014.

Acknowledgement

I would like to thank and acknowledge the assistance of Professor Geoffrey Davidson, Dr Richard Couper, Professor Gordon Howarth, Professor Peter Baghurst, Professor Ross Butler and Dr David Moore who reviewed my thesis and provided constructive feedback.

I am deeply grateful towards Dr Paul Hammond and his staff for allowing me access to his patient files of children with inflammatory bowel disease who were diagnosed and managed outside of the Women's and Children's Hospital.

I would like to acknowledge the assistance of Thomas Sullivan and Suzanne Edwards from the Data Management and Analysis Centre at the University of Adelaide who provided valuable advice on statistical analysis of the various disease course parameters and, importantly undertook the analysis of temporal changes in anthropometric parameters in South Australian children.

In addition, I would like to acknowledge the great help provided by Dr Simon Barry, PhD co-ordinator, who encouraged the supervisors to review the thesis and provided moral support during times when completion appeared to be difficult.

I am grateful for being awarded the Population Health Medical Post-Graduate Scholarship from the Women's and Children's Hospital Foundation over the three year period, allowing me to take leave from clinical work to undertake this research.

Finally, I would like to thank my wife, Rima, and my two sons, Rabieh and Hani, who were my backbone in undertaking and completing the research. They provided emotional and moral support during difficult times, tolerated my complaints, and understanding of the time spent away from them.